Genmab — December 2020
-
-
-
more on Regeneron pauses studies of a key cancer drug, citing safety concerns - https://www.biopharmadive.com/news/regeneron-pause-enrollment-lymphoma-drug/592209/
-
@Klarussen - Var du ikke ved at sælge for 3500 forleden? Satser på +5000 i 2025 - mission "Fully integrated biotech powerhouse". Så bliver det tid til kurspleje med aktietilbagekøb og dividende
-
og Jan W. kan trække sig tilbage med historien o
m, at han tog aktien fra 50 til 5000 -
Hu hej...hvor det går.
-
Er det ikke korrekt forstået at Roches glofitamab har mange flere grade 3 og 4 AE's end epco ? Det er da en stor fordel for epco ! https://haematologisktidsskrift.dk/sygdomme/lymfoma/786-bispecifikke-antistoffer-viser-stadig-imponerende-responsrater-mod-lymfekraeft.html
-
De har flere, men vel ikke mange flere...
-
Epco har ingen grade 3/4, mens Glofitamab havde 1 grade 3 of en grade 4
-
AE hos Glofitamab var primært i de 2 første behandlinger
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind